Results 151 to 160 of about 8,815 (184)

Drug-coated balloon angioplasty versus conventional angioplasty for symptomatic non-acute intracranial artery occlusion. [PDF]

Front Neurol
Dong K, Chen Y, Song Y, Sun L, Zheng M, Yin H, Zhang J, Li S, Yin T, Wang W, Meng Y, Li W, He X, Zhu C, Zhao W, Han J.   +15 more
europepmc   +1 more source

Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Treatment for Large Vessel Coronary Artery Disease. [PDF]

Catheter Cardiovasc Interv
Shin ES, Jang MH, Kim S, Kang DO, Her AY, Sohn CB.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

[Drug-coated balloons in PAD].

Deutsche medizinische Wochenschrift (1946), 2022
A large proportion of patients with peripheral arterial disease (PAD) remain asymptomatic with respect to peripheral reduced perfusion. Most symptomatic patients present with walking distance limitation, intermittent claudication. In the advanced stage, critical limb ischemia, rest pain, gangrene, or ulceration occur.Treatment goals for patients with ...
Tanja, Böhme, Thomas, Zeller
openaire   +2 more sources

Drug-Coated Percutaneous Balloon Catheters

Critical Reviews in Biomedical Engineering, 2014
Percutaneous transluminal angioplasty revolutionized coronary and peripheral revascularization. However, it is always accompanied by major drawbacks such as elastic recoil and neointimal hyperplasia. Percutaneous transluminal angioplasty along with bare metal stents reduced elastic recoil, but in-stent restenosis (ISR) and peripheral artery stenting ...
Jayesh V, Betala, Eugene M, Langan Iii, Martine, LaBerge   +2 more
openaire   +2 more sources

Stellarex drug-coated balloon: a technology evaluation

Expert Opinion on Drug Delivery, 2020
The Stellarex® drug-coated balloon (DCB) is an over-the-wire dual lumen catheter with a distally premounted semi-compliant balloon, which has a low dose (2 μg/mm2 of the expanded balloon surface) paclitaxel coating. Its hybrid formulation, made of amorphous and crystalline paclitaxel combined with a polyethylene glycol excipient, provides maintenance ...
Nerla R., Castriota F., Cremonesi A., Micari A.   +3 more
openaire   +2 more sources

Drug-coated balloons in interventional cardiology

Expert Review of Cardiovascular Therapy, 2013
Over the last few years, drug-coated balloon (DCB) therapy has emerged as a promising therapeutic intervention for the management of obstructive cardiovascular disease. The dictum of this novel technology is that effective prevention of restenosis can be achieved by the short-term transfer of antiproliferative drug to local arterial tissue by means of ...
Francesco, Giannini, Charbel, Naim, Charis, Costopoulos, Azeem, Latib, Antonio, Colombo   +4 more
openaire   +2 more sources

Drug-Coated Balloons: Technologies and Clinical Applications

Current Pharmaceutical Design, 2018
The progress and development of drug-coated balloons (DCBs) represents an emerging alternative treatment in peripheral and coronary artery diseases, particularly when a non-stent approach is necessary. Several studies and meta-analyses have evaluated the clinical outcomes of DCBs in different lesions and this review aims to compile the progress and ...
Huiying, Ang, Jinjie, Lin, Ying Ying, Huang, Tze Tec, Chong, Salvatore, Cassese, Michael, Joner, Nicolas, Foin   +6 more
openaire   +2 more sources

Drug-coated balloon in peripheral artery disease

Cardiovascular Revascularization Medicine, 2019
Peripheral artery disease (PAD) is highly prevalent but is often underdiagnosed and undertreated. Lower extremity PAD can often be life style limiting. Revascularization in carefully selected lower extremity PAD patients improves symptoms and functional status.
Madhan, Shanmugasundaram, Sangeetha, Murugapandian, Huu Tam, Truong, Kapildeo, Lotun, Subhash, Banerjee   +4 more
openaire   +2 more sources

Drug-Coated Balloons Applications in Interventional Cardiology

Current Pharmaceutical Design, 2018
Backgrounds: Drug coated balloons (DCBs) are new on stented-based anti-proliferative drug delivery systems, recently introduced in interventional cardiology. Their primary aim is to transfer an anti-proliferative drug to reduce the subsequent neo-intima hyperplasia and to maintain the normal vessel diameter and function.
Gianluca, Rigatelli, Marco, Zuin
openaire   +2 more sources

Balloons: Plain, Drug-Coated, and Cutting

2021
Arterial angioplasty was first reported by Dotter and Judkins in 1964 for the treatment of peripheral vascular lesions using rigid intravascular dilators. Inflation of an angioplasty balloon in the artery causes dissection of the atherosclerotic plaque and adjacent intima. The medial and adventitial layers are also dilated.
Chiranjiv Virk, Claudie Sheahan, Kevin Au, Malachi Sheahan   +3 more
openaire   +1 more source